恩扎卢胺治疗晚期前列腺癌中影像学进展与PSA升高的不一致性
该研究事后分析了两项III期试验(N=2551)中恩扎卢胺治疗mHSPC和nmCRPC患者出现影像学进展(rPD)时伴或不伴PSA升高或进展的情况。结果显示,恩扎卢胺组中相当比例患者rPD时无PSA升高或未达PSA进展标准,且rPD伴或不伴PSA变化均与更差OS相关。建议治疗期间定期影像学监测。
要点
- 恩扎卢胺治疗中rPD可无PSA升高,mHSPC和nmCRPC中比例分别为25.3%和21.9%。
- rPD伴或不伴PSA变化均与更差OS相关,提示需影像学监测。
- 恩扎卢胺组rPD患者肝转移发生率高于对照组,但样本量小。
核心结论
- 恩扎卢胺治疗mHSPC和nmCRPC时,影像学进展常不伴PSA升高或PSA进展,且预后较差,建议定期影像学监测。
研究设计与样本
- 两项III期试验(ARCHES和PROSPER)的事后分析,共2551例患者。
- ARCHES纳入mHSPC患者,PROSPER纳入nmCRPC患者,比较恩扎卢胺联合ADT与对照组。
- 分析rPD伴或不伴PSA进展或PSA升高,采用Kaplan-Meier法评估OS。
主要发现
- ARCHES中,恩扎卢胺+ADT组574例中3.5%无PSA升高、8.5%无PSA进展即出现rPD。
- ARCHES中,79例rPD患者中25.3%无PSA升高、62.0%未达PSA进展标准,对照组188例rPD中分别为7.4%和38.3%。
- PROSPER中,恩扎卢胺+ADT组933例中4.4%无PSA升高、10.3%无PSA进展即出现rPD。
- PROSPER中,187例rPD患者中21.9%无PSA升高、51.3%未达PSA进展标准,对照组224例rPD中分别为3.6%和18.8%。
- 恩扎卢胺组rPD患者肝转移发生率较对照组高5倍以上,但样本量小;rPD伴或不伴PSA变化均与更差OS相关。
临床怎么用
- 恩扎卢胺治疗mHSPC和nmCRPC期间,不应仅依赖PSA监测,应定期进行影像学评估。
局限性
- 事后分析,样本量有限,尤其肝转移分析样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In patients who received enzalutamide, we characterized the development of radiographic progression (rPD) without prostate-specific antigen (PSA) rise or progression in metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). METHODS: We conducted a post hoc analysis in two phase III trials (N = 2,551; ARCHES [ClinicalTrials.gov identifier: NCT02677896]; PROSPER [ClinicalTrials.gov identifier: NCT02003924]) for co-occurrence of rPD ± Prostate Cancer Working Group 2/3-defined PSA progression, and rPD ± any PSA rise from baseline/nadir by treatment. Kaplan-Meier methods were used for overall survival (OS) outcomes. RESULTS: In ARCHES, 3.5% and 8.5% of 574 patients with mHSPC treated with enzalutamide plus androgen-deprivation therapy (ADT) had no PSA rise or PSA progression at rPD, respectively. Of 79 patients with rPD who received enzalutamide plus ADT, 25.3% had no PSA rise and 62.0% did not meet PSA progression criteria compared with 7.4% and 38.3% of 188 patients with rPD treated with ADT alone, respectively. In PROSPER, 4.4% and 10.3% of 933 patients with nmCRPC treated with enzalutamide plus ADT had no PSA rise or PSA progression, respectively, at rPD. However, of 187 patients with rPD who received enzalutamide plus ADT, 21.9% had no PSA rise and 51.3% did not meet PSA progression criteria compared with 3.6% and 18.8% of 224 patients treated with placebo/ADT, respectively. Liver metastases were >5-fold higher in enzalutamide-treated patients with rPD events versus control, although sample size was small. Compared with no rPD, enzalutamide-treated patients with rPD ± PSA rise or progression had worse OS. CONCLUSION: Given the frequent discordance and poor prognosis of imaging-based progression in the absence of PSA changes during enzalutamide treatment in mHSPC and nmCRPC, periodic surveillance using imaging is recommended.
引用
- Armstrong AJ, Azad AA, Iguchi T, et al. Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. J Clin Oncol. 2026. PMID: 41894648. doi:10.1200/JCO-24-02829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。